Casdin Capital LLC Purchases New Position in Exscientia plc (NASDAQ:EXAI)

Casdin Capital LLC purchased a new stake in shares of Exscientia plc (NASDAQ:EXAIGet Rating) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 713,900 shares of the company’s stock, valued at approximately $14,107,000. Casdin Capital LLC owned 0.61% of Exscientia at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Novo Holdings A S purchased a new position in shares of Exscientia during the 4th quarter worth approximately $258,591,000. Bill & Melinda Gates Foundation bought a new stake in shares of Exscientia in the 4th quarter worth approximately $31,400,000. Pictet Asset Management SA bought a new stake in shares of Exscientia in the 4th quarter worth approximately $31,402,000. Mitsubishi UFJ Trust & Banking Corp bought a new position in Exscientia in the 4th quarter valued at approximately $4,200,000. Finally, Border to Coast Pensions Partnership Ltd bought a new position in Exscientia in the 4th quarter valued at approximately $2,590,413,000. Hedge funds and other institutional investors own 37.09% of the company’s stock.

Several equities analysts have recently weighed in on the company. Zacks Investment Research raised Exscientia from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Wednesday, April 13th. Morgan Stanley raised their price objective on shares of Exscientia from $20.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Monday, April 11th. Finally, The Goldman Sachs Group reduced their target price on shares of Exscientia from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday.

NASDAQ EXAI traded up $0.44 on Thursday, reaching $10.49. 544 shares of the company’s stock traded hands, compared to its average volume of 199,085. The stock has a 50 day moving average price of $12.28 and a 200-day moving average price of $16.50. Exscientia plc has a fifty-two week low of $6.56 and a fifty-two week high of $30.38. The company has a current ratio of 12.72, a quick ratio of 12.71 and a debt-to-equity ratio of 0.01.

Exscientia (NASDAQ:EXAIGet Rating) last released its quarterly earnings data on Wednesday, May 25th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). Research analysts forecast that Exscientia plc will post -0.42 earnings per share for the current year.

Exscientia Profile (Get Rating)

Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection.

Further Reading

Want to see what other hedge funds are holding EXAI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exscientia plc (NASDAQ:EXAIGet Rating).

Institutional Ownership by Quarter for Exscientia (NASDAQ:EXAI)

Receive News & Ratings for Exscientia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exscientia and related companies with MarketBeat.com's FREE daily email newsletter.